Yes, glycolysis can be a promising therapeutic target. Inhibiting glycolytic enzymes can disrupt the energy supply and biosynthetic machinery of pathogens. For example, targeting hexokinase or phosphofructokinase has shown potential in treating infections caused by Trypanosoma brucei (responsible for African sleeping sickness) and Leishmania species.
